Tacrolimus and vitiligo

TACROLIMUS AND VITILIGO

astellas protopic

Vitiligo treatments. Support forum Medications tips for chronic skin conditionsAmerican Academy of Dermatology. Study Confirms Effectiveness of Revolutionary Vitiligo Treatment SCHAUMBURG, IL (July 12, 2001) – Imagine feeling perfectly healthy on the inside, but on the outside something looks wrong. For millions of people who suffer from vitiligo, a disease in which patients experience a complete loss of pigment in localized areas of the skin, this feeling is one they know all too well. In a new study by dermatologist Henry W. Lim, MD, chairman of the department of dermatology at Henry Ford Hospital, Detroit, Mich., the effectiveness of narrow-band UVB (NB-UVB) phototherapy as treatment for vitiligo was examined in a small sampling of patients. The results of the study are promising for this often hard-to-treat skin condition. After completing an average of 19 treatments with NB-UVB phototherapy, five of the seven vitiligo patients that participated in the study showed greater than 75 percent repigmentation. Additionally, one patient has remained repigmented 11 months after phototherapy was discontinued. The successful repigmentation that these patients experienced is quite remarkable, explained Dr. Lim, co-author of Narrow-Band Ultraviolet B is a Useful and Well-Tolerated Treatment for Vitiligo published in the June 2001 issue of the Journal of the American Academy of Dermatology. Vitiligo is a difficult skin condition to treat, and patients are often frustrated because results from some of the other current treatments are not nearly as favourable.